Table 2. Treatment‐emergent adverse events: any‐grade events ≥15% by study part, regardless of relatedness.

Abbreviations: CCA, cholangiocarcinoma; GEJ, gastroesophageal junction; HNSCC, head and neck squamous cell cancer; SOC, system organ class; TEAEs, treatment‐emergent adverse events.